This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dose of Norepinephrine and the Concentration of L-Lactate in the Rectum and Stomach in Patients With Septic Shock.

This study has been completed.
Information provided by:
Herlev Hospital Identifier:
First received: September 14, 2005
Last updated: September 19, 2006
Last verified: September 2006

Norepinephrine is a drug used to increase blood pressure in patients with life-threatening infection. However, norepinephrine may limit the bloodflow to the gut, thereby causing relative lack of oxygen to the cells. This leads to increased formation of lactic acid.

This study examines whether increasing the dose of norepinephrine leads to higher concentrations of lactic acid in the rectum and stomach in patients with life-threatening infection.

Condition Intervention
Septic Shock Drug: Changing dose of norepinephrine and blood pressure

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Herlev Hospital:

Primary Outcome Measures:
  • L-lactate concentration in the rectum and stomach.

Estimated Enrollment: 10
Study Start Date: October 2004
Estimated Study Completion Date: December 2005

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Septic shock
  • NE-dose > 0.1 microg/kg/min
  • CI > 3.0 l/min/m2

Exclusion Criteria:

  • Age < 18, unable to obtain informed consent from relatives
  • Untreated hypertension
  • Pregnancy
  • Pathology in the rectum or stomach
  • Limitation of therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00197886

Dept. of Intensive Care, Herlev University Hospital
Herlev, Denmark, 2730
Sponsors and Collaborators
Herlev Hospital
Study Chair: Anders Perner, MD,PhD Dept. of Anaesthesia and Intensive Care, Herlev University Hospital, DK-2730 Herlev
  More Information Identifier: NCT00197886     History of Changes
Other Study ID Numbers: 2004-7041-20
Study First Received: September 14, 2005
Last Updated: September 19, 2006

Additional relevant MeSH terms:
Shock, Septic
Pathologic Processes
Systemic Inflammatory Response Syndrome
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents processed this record on September 19, 2017